

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2021/173723 A8

(43) International Publication Date
02 September 2021 (02.09.2021)

WIPO | PCT

(51) International Patent Classification:

A61K 31/704 (2006.01) *A61P 35/00* (2006.01)
A61K 38/13 (2006.01) *A61P 35/04* (2006.01)
A61K 45/06 (2006.01)

Patrick, R.; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **FOSTER, Robert, T.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(21) International Application Number:

PCT/US2021/019480

(74) **Agent: CHANG, Y., Paul**; Sheppard Mullin Richter & Hampton LLP, 12275 El Camino Real, Suite 100, San Diego, CA 92130 (US).

(22) International Filing Date:

24 February 2021 (24.02.2021)

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/981,383 25 February 2020 (25.02.2020) US


(71) Applicant: **HEPION PHARMACEUTICALS, INC.**

[US/US]; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US).

(72) **Inventors: URE, Daren, R.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **TREPANIER, Daniel, J.**; 399 Thornall Street, 1st Floor, Edison, NJ 08837 (US). **MAYO,**

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: USE OF CYCLOSPORINE ANALOGUES FOR TREATING CANCER

**FIG. 1A**

(57) **Abstract:** Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating proliferative diseases such as cancer. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

25 August 2022 (25.08.2022)

(15) Information about Correction:

see Notice of 25 August 2022 (25.08.2022)